Alkermes exec sells 9,000 shares, exercises options
A Rule 10b5-1 trading plan adopted on 2025-03-14 covered the option exercise and 9,000-share sale reported in a Form 4.
Rhea-AI Filing Summary
Alkermes plc (ALKS) reported insider activity by Craig C. Hopkinson, EVP R&D and Chief Medical Officer. On 2026-09-01, he exercised 5,000 Employee Stock Options at an exercise price of $24.59 per share to acquire 5,000 Ordinary Shares, and sold 9,000 Ordinary Shares at a weighted average price of $46.986 per share. The option exercise and sale were effected pursuant to a Rule 10b5-1 trading plan adopted on 2025-03-14. After the option exercise, he held 61,276 stock options of this grant, which are fully vested in accordance with their terms.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
3 txns
Insider
Hopkinson Craig C.
Role
EVP R&D, Chief Medical Officer
Sold
9,000 shs ($423K)
Approx. gross sale proceeds
$423K
Approx. exercise cost
$123K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (Right to Buy) F1, F4 | 5,000 | $0.00 | $0.00 |
| Exercise | Ordinary Shares F1 | 5,000 | $24.59 | $123K |
| Sale | Ordinary Shares F2, F3 | 9,000 | $46.986 | $423K |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 61,276 contracts (Direct);
Ordinary Shares — 65,389 shares (Direct)
Footnotes (4)
- F1. This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
- F2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
- F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.8269 to $47.3197. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.
- F4. These options are fully vested in accordance with their terms.
Key Figures
Options exercised: 5,000 Employee Stock Options
Option exercise price: $24.59 per share
Shares sold: 9,000 Ordinary Shares
+4 more
7 metrics
Options exercised
5,000 Employee Stock Options
Exercised on 2026-09-01 into 5,000 Ordinary Shares
Option exercise price
$24.59 per share
Exercise price for 5,000 Employee Stock Options
Shares sold
9,000 Ordinary Shares
Sale on 2026-09-01 in open market or private transactions
Weighted average sale price
$46.986 per share
Weighted average price for 9,000 shares sold; range $46.8269–$47.3197
Options held after transaction
61,276 Employee Stock Options
Derivative securities beneficially owned following the option exercise
Option expiration date
2032-02-18
Expiration date of the Employee Stock Options exercised
Rule 10b5-1 plan adoption date
2025-03-14
Date the trading plan governing the exercise and sale was adopted
Key Terms
Rule 10b5-1 trading plan, weighted average price, Employee Stock Option (Right to Buy), derivative security
4 terms
Rule 10b5-1 trading plan regulatory
"This option exercise was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Employee Stock Option (Right to Buy) financial
"security_title: Employee Stock Option (Right to Buy)"
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
What insider transactions did ALKS executive Craig C. Hopkinson report on this Form 4?
Craig C. Hopkinson reported exercising 5,000 stock options at an exercise price of $24.59 per share into 5,000 Ordinary Shares and selling 9,000 Ordinary Shares at a weighted average price of $46.986 per share on 2026-09-01.
Were Craig C. Hopkinson’s ALKS trades made under a Rule 10b5-1 plan?
Yes. Both the option exercise and the sale of Ordinary Shares were effected pursuant to a Rule 10b5-1 trading plan adopted on 2025-03-14, as disclosed in the footnotes.
What options did Craig C. Hopkinson exercise in this ALKS Form 4 filing?
He exercised 5,000 Employee Stock Options to buy Ordinary Shares at an exercise price of $24.59 per share. These options are reported as fully vested in accordance with their terms and have an expiration date of 2032-02-18.
How many Alkermes (ALKS) stock options does Craig C. Hopkinson hold after this transaction?
Following the reported option exercise, Craig C. Hopkinson holds 61,276 Employee Stock Options of this grant, as shown in the Form 4 data for derivative securities beneficially owned following the transaction.
What is the net effect of Craig C. Hopkinson’s September 1, 2026 ALKS transactions?
On 2026-09-01, he exercised 5,000 options to acquire 5,000 shares and sold 9,000 shares. The filing’s transaction summary shows net-sell activity of 9,000 shares, along with continued ownership of 61,276 stock options from this grant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
